Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 13/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 13/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | USP1 | O94782 | 1/20 | 0.30 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1407370 | 0.89 | NR1H2 (0.52) | NR1H2NR1H3NR1I2NR3C1AR | |
| SCHEMBL1407789 | 0.83 | NR1H2 (0.53) | NR1H2NR1H3NR1I2NR3C1AR | |
| SCHEMBL1407119 | 0.83 | NR1H2 (0.51) | NR1H2NR1H3NR1I2NR3C1AR | |
| SCHEMBL1407493 | 0.82 | NR1H2 (0.50) | NR1H2NR1H3NR1I2NR3C1AR | |
| SCHEMBL3862040 | 0.81 | NR1H2 (0.44) | NR1H2NR1H3NR1I2NR3C1AR | |
| SCHEMBL1407577 | 0.81 | NR1H2 (0.52) | NR1H2NR1H3NR1I2NR3C1AR | |
| SCHEMBL1414709 | 0.81 | NR1H2 (0.48) | NR1H2NR1H3NR1I2NR3C1AR | |
| SCHEMBL1407174 | 0.81 | NR1H2 (0.48) | NR1H2NR1H3NR1I2NR3C1AR | |
| SCHEMBL1407702 | 0.81 | NR1H2 (0.54) | NR1H2NR1H3NR1I2NR3C1AR | |
| SCHEMBL1407380 | 0.81 | NR1H2 (0.54) | NR1H2NR1H3NR1I2NR3C1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295429-A1 | 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases | Wyeth LLC (US) | 2011-03-16 | — | — | EP | disclosed |